Posted from: Monday, February 01, 2016 - 01:32 PM - Present

Kyprolis Combination Therapy Approved

January 21, 2016 – The U.S. Food and Drug Administration (FDA) approved Kyprolis (carfilzomib) for use in combination with dexamethasone or Revlimid (lenalidomide – Celgene) plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. Full approval was also granted for the use of Kyprolis as a single agent to treat patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. Kyprolis, manufactured by Amgen, is an infused proteasome inhibitor that was first approved in July 2012.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, August 23, 2017 - 02:01 PM.